 | • レポートコード：MRC2-11QY11815 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は子宮内膜症治療薬のグローバル市場について調査・分析したレポートです。種類別（ホルモン療法、アドバック薬、プロゲストーゲン、漢方薬）市場規模、用途別（病院、クリニック、研究機関）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別子宮内膜症治療薬の競争状況、市場シェア ・世界の子宮内膜症治療薬市場：種類別市場規模 2015年-2020年（ホルモン療法、アドバック薬、プロゲストーゲン、漢方薬） ・世界の子宮内膜症治療薬市場：種類別市場規模予測 2021年-2026年（ホルモン療法、アドバック薬、プロゲストーゲン、漢方薬） ・世界の子宮内膜症治療薬市場：用途別市場規模 2015年-2020年（病院、クリニック、研究機関） ・世界の子宮内膜症治療薬市場：用途別市場規模予測 2021年-2026年（病院、クリニック、研究機関） ・北米の子宮内膜症治療薬市場分析：米国、カナダ ・ヨーロッパの子宮内膜症治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの子宮内膜症治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の子宮内膜症治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの子宮内膜症治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AbbVie、Astellas Pharma、AstraZeneca、Debiopharm Group、Evotec AG、Kissei Pharmaceutical、Neurocrine Biosciences、ObsEva、Pfizer、Repros Therapeutics、Roivant Sciences GmbH、Takeda Pharmaceutical Company Limited、ValiRx ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Endometriosis affects an estimated 1 in 10 women in the reproductive age group of 15-49 years.
Among these therapies, Elagolix, a first-in-class GnRH receptor antagonist, is closest to market.
Market Analysis and Insights: Global Endometriosis Drugs Market
The global Endometriosis Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Endometriosis Drugs Scope and Market Size
Endometriosis Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Endometriosis Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
AbbVie
Astellas Pharma
AstraZeneca
Debiopharm Group
Evotec AG
Kissei Pharmaceutical
Neurocrine Biosciences
ObsEva
Pfizer
Repros Therapeutics
Roivant Sciences GmbH
Takeda Pharmaceutical Company Limited
ValiRx
Market segment by Type, the product can be split into
Hormonal Therapy
Add-back Medication
Progestogens
Chinese Herbs
Market segment by Application, split into
Hospitals
Clinics
Research Institutes
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Endometriosis Drugs Revenue
1.4 Market by Type
1.4.1 Global Endometriosis Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Hormonal Therapy
1.4.3 Add-back Medication
1.4.4 Progestogens
1.4.5 Chinese Herbs
1.5 Market by Application
1.5.1 Global Endometriosis Drugs Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Research Institutes
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Endometriosis Drugs Market Perspective (2015-2026)
2.2 Global Endometriosis Drugs Growth Trends by Regions
2.2.1 Endometriosis Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Endometriosis Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Endometriosis Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Endometriosis Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Endometriosis Drugs Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Endometriosis Drugs Players by Market Size
3.1.1 Global Top Endometriosis Drugs Players by Revenue (2015-2020)
3.1.2 Global Endometriosis Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Endometriosis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Endometriosis Drugs Market Concentration Ratio
3.2.1 Global Endometriosis Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Endometriosis Drugs Revenue in 2019
3.3 Endometriosis Drugs Key Players Head office and Area Served
3.4 Key Players Endometriosis Drugs Product Solution and Service
3.5 Date of Enter into Endometriosis Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Endometriosis Drugs Historic Market Size by Type (2015-2020)
4.2 Global Endometriosis Drugs Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Endometriosis Drugs Market Size by Application (2015-2020)
5.2 Global Endometriosis Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Endometriosis Drugs Market Size (2015-2020)
6.2 Endometriosis Drugs Key Players in North America (2019-2020)
6.3 North America Endometriosis Drugs Market Size by Type (2015-2020)
6.4 North America Endometriosis Drugs Market Size by Application (2015-2020)
7 Europe
7.1 Europe Endometriosis Drugs Market Size (2015-2020)
7.2 Endometriosis Drugs Key Players in Europe (2019-2020)
7.3 Europe Endometriosis Drugs Market Size by Type (2015-2020)
7.4 Europe Endometriosis Drugs Market Size by Application (2015-2020)
8 China
8.1 China Endometriosis Drugs Market Size (2015-2020)
8.2 Endometriosis Drugs Key Players in China (2019-2020)
8.3 China Endometriosis Drugs Market Size by Type (2015-2020)
8.4 China Endometriosis Drugs Market Size by Application (2015-2020)
9 Japan
9.1 Japan Endometriosis Drugs Market Size (2015-2020)
9.2 Endometriosis Drugs Key Players in Japan (2019-2020)
9.3 Japan Endometriosis Drugs Market Size by Type (2015-2020)
9.4 Japan Endometriosis Drugs Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Endometriosis Drugs Market Size (2015-2020)
10.2 Endometriosis Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Endometriosis Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Endometriosis Drugs Market Size by Application (2015-2020)
11 India
11.1 India Endometriosis Drugs Market Size (2015-2020)
11.2 Endometriosis Drugs Key Players in India (2019-2020)
11.3 India Endometriosis Drugs Market Size by Type (2015-2020)
11.4 India Endometriosis Drugs Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Endometriosis Drugs Market Size (2015-2020)
12.2 Endometriosis Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Endometriosis Drugs Market Size by Type (2015-2020)
12.4 Central & South America Endometriosis Drugs Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 AbbVie
13.1.1 AbbVie Company Details
13.1.2 AbbVie Business Overview
13.1.3 AbbVie Endometriosis Drugs Introduction
13.1.4 AbbVie Revenue in Endometriosis Drugs Business (2015-2020))
13.1.5 AbbVie Recent Development
13.2 Astellas Pharma
13.2.1 Astellas Pharma Company Details
13.2.2 Astellas Pharma Business Overview
13.2.3 Astellas Pharma Endometriosis Drugs Introduction
13.2.4 Astellas Pharma Revenue in Endometriosis Drugs Business (2015-2020)
13.2.5 Astellas Pharma Recent Development
13.3 AstraZeneca
13.3.1 AstraZeneca Company Details
13.3.2 AstraZeneca Business Overview
13.3.3 AstraZeneca Endometriosis Drugs Introduction
13.3.4 AstraZeneca Revenue in Endometriosis Drugs Business (2015-2020)
13.3.5 AstraZeneca Recent Development
13.4 Debiopharm Group
13.4.1 Debiopharm Group Company Details
13.4.2 Debiopharm Group Business Overview
13.4.3 Debiopharm Group Endometriosis Drugs Introduction
13.4.4 Debiopharm Group Revenue in Endometriosis Drugs Business (2015-2020)
13.4.5 Debiopharm Group Recent Development
13.5 Evotec AG
13.5.1 Evotec AG Company Details
13.5.2 Evotec AG Business Overview
13.5.3 Evotec AG Endometriosis Drugs Introduction
13.5.4 Evotec AG Revenue in Endometriosis Drugs Business (2015-2020)
13.5.5 Evotec AG Recent Development
13.6 Kissei Pharmaceutical
13.6.1 Kissei Pharmaceutical Company Details
13.6.2 Kissei Pharmaceutical Business Overview
13.6.3 Kissei Pharmaceutical Endometriosis Drugs Introduction
13.6.4 Kissei Pharmaceutical Revenue in Endometriosis Drugs Business (2015-2020)
13.6.5 Kissei Pharmaceutical Recent Development
13.7 Neurocrine Biosciences
13.7.1 Neurocrine Biosciences Company Details
13.7.2 Neurocrine Biosciences Business Overview
13.7.3 Neurocrine Biosciences Endometriosis Drugs Introduction
13.7.4 Neurocrine Biosciences Revenue in Endometriosis Drugs Business (2015-2020)
13.7.5 Neurocrine Biosciences Recent Development
13.8 ObsEva
13.8.1 ObsEva Company Details
13.8.2 ObsEva Business Overview
13.8.3 ObsEva Endometriosis Drugs Introduction
13.8.4 ObsEva Revenue in Endometriosis Drugs Business (2015-2020)
13.8.5 ObsEva Recent Development
13.9 Pfizer
13.9.1 Pfizer Company Details
13.9.2 Pfizer Business Overview
13.9.3 Pfizer Endometriosis Drugs Introduction
13.9.4 Pfizer Revenue in Endometriosis Drugs Business (2015-2020)
13.9.5 Pfizer Recent Development
13.10 Repros Therapeutics
13.10.1 Repros Therapeutics Company Details
13.10.2 Repros Therapeutics Business Overview
13.10.3 Repros Therapeutics Endometriosis Drugs Introduction
13.10.4 Repros Therapeutics Revenue in Endometriosis Drugs Business (2015-2020)
13.10.5 Repros Therapeutics Recent Development
13.11 Roivant Sciences GmbH
10.11.1 Roivant Sciences GmbH Company Details
10.11.2 Roivant Sciences GmbH Business Overview
10.11.3 Roivant Sciences GmbH Endometriosis Drugs Introduction
10.11.4 Roivant Sciences GmbH Revenue in Endometriosis Drugs Business (2015-2020)
10.11.5 Roivant Sciences GmbH Recent Development
13.12 Takeda Pharmaceutical Company Limited
10.12.1 Takeda Pharmaceutical Company Limited Company Details
10.12.2 Takeda Pharmaceutical Company Limited Business Overview
10.12.3 Takeda Pharmaceutical Company Limited Endometriosis Drugs Introduction
10.12.4 Takeda Pharmaceutical Company Limited Revenue in Endometriosis Drugs Business (2015-2020)
10.12.5 Takeda Pharmaceutical Company Limited Recent Development
13.13 ValiRx
10.13.1 ValiRx Company Details
10.13.2 ValiRx Business Overview
10.13.3 ValiRx Endometriosis Drugs Introduction
10.13.4 ValiRx Revenue in Endometriosis Drugs Business (2015-2020)
10.13.5 ValiRx Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Endometriosis Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Endometriosis Drugs Revenue
Table 3. Ranking of Global Top Endometriosis Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Endometriosis Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Hormonal Therapy
Table 6. Key Players of Add-back Medication
Table 7. Key Players of Progestogens
Table 8. Key Players of Chinese Herbs
Table 9. Global Endometriosis Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Endometriosis Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Endometriosis Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Endometriosis Drugs Market Share by Regions (2015-2020)
Table 13. Global Endometriosis Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Endometriosis Drugs Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Endometriosis Drugs Market Growth Strategy
Table 19. Main Points Interviewed from Key Endometriosis Drugs Players
Table 20. Global Endometriosis Drugs Revenue by Players (2015-2020) (Million US$)
Table 21. Global Endometriosis Drugs Market Share by Players (2015-2020)
Table 22. Global Top Endometriosis Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Endometriosis Drugs as of 2019)
Table 23. Global Endometriosis Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Endometriosis Drugs Product Solution and Service
Table 26. Date of Enter into Endometriosis Drugs Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Endometriosis Drugs Market Size by Type (2015-2020) (Million US$)
Table 29. Global Endometriosis Drugs Market Size Share by Type (2015-2020)
Table 30. Global Endometriosis Drugs Revenue Market Share by Type (2021-2026)
Table 31. Global Endometriosis Drugs Market Size Share by Application (2015-2020)
Table 32. Global Endometriosis Drugs Market Size by Application (2015-2020) (Million US$)
Table 33. Global Endometriosis Drugs Market Size Share by Application (2021-2026)
Table 34. North America Key Players Endometriosis Drugs Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Endometriosis Drugs Market Share (2019-2020)
Table 36. North America Endometriosis Drugs Market Size by Type (2015-2020) (Million US$)
Table 37. North America Endometriosis Drugs Market Share by Type (2015-2020)
Table 38. North America Endometriosis Drugs Market Size by Application (2015-2020) (Million US$)
Table 39. North America Endometriosis Drugs Market Share by Application (2015-2020)
Table 40. Europe Key Players Endometriosis Drugs Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Endometriosis Drugs Market Share (2019-2020)
Table 42. Europe Endometriosis Drugs Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Endometriosis Drugs Market Share by Type (2015-2020)
Table 44. Europe Endometriosis Drugs Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Endometriosis Drugs Market Share by Application (2015-2020)
Table 46. China Key Players Endometriosis Drugs Revenue (2019-2020) (Million US$)
Table 47. China Key Players Endometriosis Drugs Market Share (2019-2020)
Table 48. China Endometriosis Drugs Market Size by Type (2015-2020) (Million US$)
Table 49. China Endometriosis Drugs Market Share by Type (2015-2020)
Table 50. China Endometriosis Drugs Market Size by Application (2015-2020) (Million US$)
Table 51. China Endometriosis Drugs Market Share by Application (2015-2020)
Table 52. Japan Key Players Endometriosis Drugs Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Endometriosis Drugs Market Share (2019-2020)
Table 54. Japan Endometriosis Drugs Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Endometriosis Drugs Market Share by Type (2015-2020)
Table 56. Japan Endometriosis Drugs Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Endometriosis Drugs Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Endometriosis Drugs Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Endometriosis Drugs Market Share (2019-2020)
Table 60. Southeast Asia Endometriosis Drugs Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Endometriosis Drugs Market Share by Type (2015-2020)
Table 62. Southeast Asia Endometriosis Drugs Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Endometriosis Drugs Market Share by Application (2015-2020)
Table 64. India Key Players Endometriosis Drugs Revenue (2019-2020) (Million US$)
Table 65. India Key Players Endometriosis Drugs Market Share (2019-2020)
Table 66. India Endometriosis Drugs Market Size by Type (2015-2020) (Million US$)
Table 67. India Endometriosis Drugs Market Share by Type (2015-2020)
Table 68. India Endometriosis Drugs Market Size by Application (2015-2020) (Million US$)
Table 69. India Endometriosis Drugs Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Endometriosis Drugs Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Endometriosis Drugs Market Share (2019-2020)
Table 72. Central & South America Endometriosis Drugs Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Endometriosis Drugs Market Share by Type (2015-2020)
Table 74. Central & South America Endometriosis Drugs Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Endometriosis Drugs Market Share by Application (2015-2020)
Table 76. AbbVie Company Details
Table 77. AbbVie Business Overview
Table 78. AbbVie Product
Table 79. AbbVie Revenue in Endometriosis Drugs Business (2015-2020) (Million US$)
Table 80. AbbVie Recent Development
Table 81. Astellas Pharma Company Details
Table 82. Astellas Pharma Business Overview
Table 83. Astellas Pharma Product
Table 84. Astellas Pharma Revenue in Endometriosis Drugs Business (2015-2020) (Million US$)
Table 85. Astellas Pharma Recent Development
Table 86. AstraZeneca Company Details
Table 87. AstraZeneca Business Overview
Table 88. AstraZeneca Product
Table 89. AstraZeneca Revenue in Endometriosis Drugs Business (2015-2020) (Million US$)
Table 90. AstraZeneca Recent Development
Table 91. Debiopharm Group Company Details
Table 92. Debiopharm Group Business Overview
Table 93. Debiopharm Group Product
Table 94. Debiopharm Group Revenue in Endometriosis Drugs Business (2015-2020) (Million US$)
Table 95. Debiopharm Group Recent Development
Table 96. Evotec AG Company Details
Table 97. Evotec AG Business Overview
Table 98. Evotec AG Product
Table 99. Evotec AG Revenue in Endometriosis Drugs Business (2015-2020) (Million US$)
Table 100. Evotec AG Recent Development
Table 101. Kissei Pharmaceutical Company Details
Table 102. Kissei Pharmaceutical Business Overview
Table 103. Kissei Pharmaceutical Product
Table 104. Kissei Pharmaceutical Revenue in Endometriosis Drugs Business (2015-2020) (Million US$)
Table 105. Kissei Pharmaceutical Recent Development
Table 106. Neurocrine Biosciences Company Details
Table 107. Neurocrine Biosciences Business Overview
Table 108. Neurocrine Biosciences Product
Table 109. Neurocrine Biosciences Revenue in Endometriosis Drugs Business (2015-2020) (Million US$)
Table 110. Neurocrine Biosciences Recent Development
Table 111. ObsEva Business Overview
Table 112. ObsEva Product
Table 113. ObsEva Company Details
Table 114. ObsEva Revenue in Endometriosis Drugs Business (2015-2020) (Million US$)
Table 115. ObsEva Recent Development
Table 116. Pfizer Company Details
Table 117. Pfizer Business Overview
Table 118. Pfizer Product
Table 119. Pfizer Revenue in Endometriosis Drugs Business (2015-2020) (Million US$)
Table 120. Pfizer Recent Development
Table 121. Repros Therapeutics Company Details
Table 122. Repros Therapeutics Business Overview
Table 123. Repros Therapeutics Product
Table 124. Repros Therapeutics Revenue in Endometriosis Drugs Business (2015-2020) (Million US$)
Table 125. Repros Therapeutics Recent Development
Table 126. Roivant Sciences GmbH Company Details
Table 127. Roivant Sciences GmbH Business Overview
Table 128. Roivant Sciences GmbH Product
Table 129. Roivant Sciences GmbH Revenue in Endometriosis Drugs Business (2015-2020) (Million US$)
Table 130. Roivant Sciences GmbH Recent Development
Table 131. Takeda Pharmaceutical Company Limited Company Details
Table 132. Takeda Pharmaceutical Company Limited Business Overview
Table 133. Takeda Pharmaceutical Company Limited Product
Table 134. Takeda Pharmaceutical Company Limited Revenue in Endometriosis Drugs Business (2015-2020) (Million US$)
Table 135. Takeda Pharmaceutical Company Limited Recent Development
Table 136. ValiRx Company Details
Table 137. ValiRx Business Overview
Table 138. ValiRx Product
Table 139. ValiRx Revenue in Endometriosis Drugs Business (2015-2020) (Million US$)
Table 140. ValiRx Recent Development
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Endometriosis Drugs Market Share by Type: 2020 VS 2026
Figure 2. Hormonal Therapy Features
Figure 3. Add-back Medication Features
Figure 4. Progestogens Features
Figure 5. Chinese Herbs Features
Figure 6. Global Endometriosis Drugs Market Share by Application: 2020 VS 2026
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Research Institutes Case Studies
Figure 10. Endometriosis Drugs Report Years Considered
Figure 11. Global Endometriosis Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Endometriosis Drugs Market Share by Regions: 2020 VS 2026
Figure 13. Global Endometriosis Drugs Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Endometriosis Drugs Market Share by Players in 2019
Figure 16. Global Top Endometriosis Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Endometriosis Drugs as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Endometriosis Drugs Revenue in 2019
Figure 18. North America Endometriosis Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Endometriosis Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Endometriosis Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Endometriosis Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Endometriosis Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Endometriosis Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Endometriosis Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed
子宮内膜症の世界市場（～2026年） Endometriosis is a medical condition in which the tissue that forms normal lining of uterus appears outside the uterus cavity and may involve ovaries, bowel or tissue lining of the pelvic floor. Rising incidences of endometriosis due to diagnostic improvements leading to early identification, enviro…- 画期的治療薬の世界市場（～2026年） Breakthrough therapy drugs are intended to treat serious and life-threatening conditions. The breakthrough therapy is the designation given by FDA for the drugs when there is a preliminary clinical evidence indicates that the drug proves a substantial improvement over available drug treatment. Two f…
- 泌尿生殖器治療薬の世界市場（～2026年） A medical science concerned with the study and treatment of diseases of the genital and urinary organs, especially sexually transmitted diseases. The growing prevalence of genitourinary disorders is presumed to be the high rendering impact driver of this vertical. In addition, increasing number of p…
- テネクテプラーゼ薬の世界市場（～2026年） Tenecteplase drug is an enzyme derived through recombinant DNA technology from a human cell line. This enzyme is used to treat thrombus (blood clots) it is also called as clot-busting drug. Tenecteplase is a bioengineered variant of the activase drug. It is estimated that North America dominated the…
- チロシンヒドロキシラーゼ欠損症治療薬の世界市場（～2026年） The Tyrosine Hydroxylase Deficiency is also known as recessive dopa-responsive dystonia and is a rare genetic disorder. In the Tyrosine Hydroxylase Deficiency, there is lack of enzymes which are involved in converting amino acid tyrosine to L-dopa. A wide range of symptoms can be associated with the…